Despite the prevalence and apparent reliance on PI3K signaling in glioma, PI3K inhibitors exert cytostatic rather than cytotoxic effects in glioma cell lines and xenografts even when combined with inhibitors of the epidermal growth factor receptor (EGFR) and mTOR [22]. The gene discussed is MTOR; the disease is central nervous system cancer.